Ascorbic acid has superior ex vivo antiproliferative, cell death-inducing and immunomodulatory effects over IFN-α in HTLV-1-associated myelopathy

PLoS Neglected Tropical Diseases

Volumn 6, Issue 7, 2012, Pages

  Moens, Britta ^a   Decanine, Daniele ^b,g   Menezes, Soraya Maria ^a   Khouri, Ricardo ^a,b   Silva Santos, Gilvanéia ^b,h   Lopez, Giovanni ^c   Alvarez, Carolina ^a,c   Talledo, Michael ^c   Gotuzzo, Eduardo ^c,d   de Almeida Kruschewsky, Ramon ^e   Galvão Castro, Bernardo ^b,e   Vandamme, Anne Mieke ^a,f   van Weyenbergh, Johan ^a,b  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^d UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^e ESCOLA BAHIANA DE MEDICINA E SAÚDE PÚBLICA   (Brazil)

^f INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^g UNIVERSIDADE CATÓLICA DOM BOSCO   (Brazil)

^h FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ASCORBIC ACID; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MICRORNA 155; TUMOR NECROSIS FACTOR ALPHA; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR;

ADULT; AGED; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL DEATH; CONTROLLED STUDY; DNA SYNTHESIS; FEMALE; FLOW CYTOMETRY; GENE CONTROL; HTLV 1 ASSOCIATED MYELOPATHY; HUMAN; HUMAN CELL; IMMUNOMODULATION; LEUKOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; TH2 CELL; TROPICAL SPASTIC PARAPARESIS; UPREGULATION; CELL CULTURE; COMPARATIVE STUDY; DRUG EFFECT; GENE EXPRESSION PROFILING; IN VITRO STUDY; MIDDLE AGED; ORGAN CULTURE TECHNIQUE; SPINAL CORD DISEASE; T CELL LEUKEMIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ASCORBIC ACID; CELL DEATH; CELLS, CULTURED; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; ORGAN CULTURE TECHNIQUES; SPINAL CORD DISEASES; YOUNG ADULT;

EID: 84864625055     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001729     Document Type: Article

References (56)

1. Maloney EM, Cleghorn FR, Morgan OS, Rodgers-Johnson P, Cranston B, et al. (1998) Incidence of HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Jamaica and Trinidad. J Acquir Immune Defic Syndr Hum Retrovirol 17: 167-170.
2. Osame M, (2002) Pathological mechanisms of human T-cell lymphotropic virus type I-associated myelopathy (HAM/TSP). J Neurovirol 8: 359-364.
3. Jacobson S, (2002) Immunopathogenesis of human T cell lymphotropic virus type I-associated neurologic disease. J Infect Dis 186: S187-192.
4. Nagai M, Yamano Y, Brennan MB, Mora CA, Jacobson S, (2001) Increased HTLV-I proviral load and preferential expansion of HTLV-I Tax-specific CD8+ T cells in cerebrospinal fluid from patients with HAM/TSP. Annals of neurology 50: 807-812.
5. Araujo A, Hall WW, (2004) Human T-lymphotropic virus type II and neurological disease. Ann Neurol 56: 10-19.
6. Izumo S, Goto I, Itoyama Y, Okajima T, Watanabe S, et al. (1996) Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial. Neurology 46: 1016-1021.
7. Kataoka A, Imai H, Inayoshi S, Tsuda T, (1993) [Intermittent high-dose vitamin C therapy in patients with HTLV-I-associated myelopathy]. Rinsho Shinkeigaku 33: 282-288.
8. Nakagawa M, Nakahara K, Maruyama Y, Kawabata M, Higuchi I, et al. (1996) Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. J Neurovirol 2: 345-355.
9. Mandl J, Szarka A, Banhegyi G, (2009) Vitamin C: update on physiology and pharmacology. British journal of pharmacology 157: 1097-1110.
10. Cameron E, Pauling L, (1978) Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proceedings of the National Academy of Sciences of the United States of America 75: 4538-4542.
11. Fromberg A, Gutsch D, Schulze D, Vollbracht C, Weiss G, et al. (2011) Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer chemotherapy and pharmacology 67: 1157-1166.
12. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, et al. (2008) Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 19: 1969-1974.
13. Hughes DA, (1999) Effects of dietary antioxidants on the immune function of middle-aged adults. The Proceedings of the Nutrition Society 58: 79-84.
14. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982.
15. Grever MR, (2010) How I treat hairy cell leukemia. Blood 115: 21-28.
16. Trinchieri G, (2010) Type I interferon: friend or foe? The Journal of experimental medicine 207: 2053-2063.
17. Harakeh S, Diab-Assaf M, Khalife JC, Abu-el-Ardat KA, Baydoun E, et al. (2007) Ascorbic acid induces apoptosis in adult T-cell leukemia. Anticancer research 27: 289-298.
18. Miyoshi I, Yoshimoto S, Kubonishi I, Taguchi H, Shiraishi Y, et al. (1981) Transformation of normal human cord lymphocytes by co-cultivation with a lethally irradiated human T-cell line carrying type C virus particles. Gann 72: 997-998.
19. Miyoshi I, Kubonishi I, Yoshimoto S, Shiraishi Y, (1981) A T-cell line derived from normal human cord leukocytes by co-culturing with human leukemic T-cells. Gann = Gan 72: 978-981.
20. Hanon E, Asquith RE, Taylor GP, Tanaka Y, Weber JN, et al. (2000) High frequency of viral protein expression in human T cell lymphotropic virus type 1-infected peripheral blood mononuclear cells. AIDS Res Hum Retroviruses 16: 1711-1715.
21. Goon PK, Igakura T, Hanon E, Mosley AJ, Asquith B, et al. (2003) High circulating frequencies of tumor necrosis factor alpha- and interleukin-2-secreting human T-lymphotropic virus type 1 (HTLV-1)-specific CD4+ T cells in patients with HTLV-1-associated neurological disease. Journal of virology 77: 9716-9722.
22. Santos SB, Porto AF, Muniz AL, de Jesus AR, Magalhaes E, et al. (2004) Exacerbated inflammatory cellular immune response characteristics of HAM/TSP is observed in a large proportion of HTLV-I asymptomatic carriers. BMC infectious diseases 4: 7.
23. Nishimoto N, Yoshizaki K, Eiraku N, Machigashira K, Tagoh H, et al. (1990) Elevated levels of interleukin-6 in serum and cerebrospinal fluid of HTLV-I-associated myelopathy/tropical spastic paraparesis. Journal of the neurological sciences 97: 183-193.
24. Feng X, Heyden NV, Ratner L, (2003) Alpha interferon inhibits human T-cell leukemia virus type 1 assembly by preventing Gag interaction with rafts. J Virol 77: 13389-13395.
25. Richardson JH, Edwards AJ, Cruickshank JK, Rudge P, Dalgleish AG, (1990) In vivo cellular tropism of human T-cell leukemia virus type 1. J Virol 64: 5682-5687.
26. Puertollano MA, Puertollano E, de Cienfuegos GA, de Pablo MA, (2011) Dietary antioxidants: immunity and host defense. Current topics in medicinal chemistry 11: 1752-1766.
27. Grassmann R, Aboud M, Jeang KT, (2005) Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene 24: 5976-5985.
28. Kchour G, Tarhini M, Sharifi N, Farid R, Khooei AR, et al. (2008) Increased microvessel density in involved organs from patients with HTLV-I associated adult T cell leukemia lymphoma. Leukemia & lymphoma 49: 265-270.
29. Washiyama M, Nishigaki K, Ahmed N, Kinpara S, Ishii Y, et al. (2007) IL-2 withdrawal induces HTLV-1 expression through p38 activation in ATL cell lines. FEBS letters 581: 5207-5212.
30. Vajente N, Trevisan R, Saggioro D, (2009) HTLV-1 Tax protein cooperates with Ras in protecting cells from apoptosis. Apoptosis: an international journal on programmed cell death 14: 153-163.
31. Jeong SJ, Pise-Masison CA, Radonovich MF, Park HU, Brady JN, (2005) Activated AKT regulates NF-kappaB activation, p53 inhibition and cell survival in HTLV-1-transformed cells. Oncogene 24: 6719-6728.
32. Fukushima N, Nishiura Y, Nakamura T, Kohno S, Eguchi K, (2007) Blockade of IL-2 receptor suppresses HTLV-I and IFN-gamma expression in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. Internal medicine 46: 347-351.
33. Azimi N, Jacobson S, Leist T, Waldmann TA, (1999) Involvement of IL-15 in the pathogenesis of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: implications for therapy with a monoclonal antibody directed to the IL-2/15R beta receptor. Journal of immunology 163: 4064-4072.
34. Santos SB, Porto AF, Muniz AL, Luna T, Nascimento MC, et al. (2006) Modulation of T cell responses in HTLV-1 carriers and in patients with myelopathy associated with HTLV-1. Neuroimmunomodulation 13: 145-151.
35. Best I, Adaui V, Verdonck K, Gonzalez E, Tipismana M, et al. (2006) Proviral load and immune markers associated with human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Peru. Clinical and experimental immunology 146: 226-233.
36. Goon PK, Hanon E, Igakura T, Tanaka Y, Weber JN, et al. (2002) High frequencies of Th1-type CD4(+) T cells specific to HTLV-1 Env and Tax proteins in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. Blood 99: 3335-3341.
37. Umehara F, Izumo S, Ronquillo AT, Matsumuro K, Sato E, et al. (1994) Cytokine expression in the spinal cord lesions in HTLV-I-associated myelopathy. Journal of neuropathology and experimental neurology 53: 72-77.
38. Kuroda Y, Matsui M, (1993) Cerebrospinal fluid interferon-gamma is increased in HTLV-I-associated myelopathy. Journal of neuroimmunology 42: 223-226.
39. Nakamura S, Nagano I, Yoshioka M, Shimazaki S, Onodera J, et al. (1993) Detection of tumor necrosis factor-alpha-positive cells in cerebrospinal fluid of patients with HTLV-I-associated myelopathy. Journal of neuroimmunology 42: 127-130.
40. Primo JR, Brites C, Oliveira Mde F, Moreno-Carvalho O, Machado M, et al. (2005) Infective dermatitis and human T cell lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis in childhood and adolescence. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 41: 535-541.
41. Kendall EA, Gonzalez E, Espinoza I, Tipismana M, Verdonck K, et al. (2009) Early neurologic abnormalities associated with human T-cell lymphotropic virus type 1 infection in a cohort of Peruvian children. The Journal of pediatrics 155: 700-706.
42. Manel N, Kim FJ, Kinet S, Taylor N, Sitbon M, et al. (2003) The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. 115: 449-459.
43. Hagiya K, Yasunaga J, Satou Y, Ohshima K, Matsuoka M, (2011) ATF3, an HTLV-1 bZip factor binding protein, promotes proliferation of adult T-cell leukemia cells. Retrovirology 8: 19.
44. Satou Y, Yasunaga J, Yoshida M, Matsuoka M, (2006) HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proceedings of the National Academy of Sciences of the United States of America 103: 720-725.
45. Arnold J, Zimmerman B, Li M, Lairmore MD, Green PL, (2008) Human T-cell leukemia virus type-1 antisense-encoded gene, Hbz, promotes T-lymphocyte proliferation. Blood 112: 3788-3797.
46. Saito M, Matsuzaki T, Satou Y, Yasunaga J, Saito K, et al. (2009) In vivo expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). Retrovirology 6: 19.
47. Wang L, Toomey NL, Diaz LA, Walker G, Ramos JC, et al. (2011) Oncogenic IRFs provide a survival advantage for Epstein-Barr virus- or human T-cell leukemia virus type 1-transformed cells through induction of BIC expression. Journal of virology 85: 8328-8337.
48. Gartel AL, Kandel ES, (2008) miRNAs: Little known mediators of oncogenesis. Seminars in cancer biology 18: 103-110.
49. Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, et al. (2007) Requirement of bic/microRNA-155 for normal immune function. Science 316: 608-611.
50. O'Connell RM, Kahn D, Gibson WS, Round JL, Scholz RL, et al. (2010) MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 33: 607-619.
51. Murugaiyan G, Beynon V, Mittal A, Joller N, Weiner HL, (2011) Silencing microRNA-155 ameliorates experimental autoimmune encephalomyelitis. Journal of immunology 187: 2213-2221.
52. Paraboschi EM, Solda G, Gemmati D, Orioli E, Zeri G, et al. (2011) Genetic association and altered gene expression of mir-155 in multiple sclerosis patients. International journal of molecular sciences 12: 8695-8712.
53. Junker A, Krumbholz M, Eisele S, Mohan H, Augstein F, et al. (2009) MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain: a journal of neurology 132: 3342-3352.
54. Trotta R, Chen L, Ciarlariello D, Josyula S, Mao C, et al. (2012) MiR-155 regulates IFN-gamma production in natural killer cells. Blood.
55. Pichler K, Schneider G, Grassmann R, (2008) MicroRNA miR-146a and further oncogenesis-related cellular microRNAs are dysregulated in HTLV-1-transformed T lymphocytes. Retrovirology 5: 100.
56. Bellon M, Lepelletier Y, Hermine O, Nicot C, (2009) Deregulation of microRNA involved in hematopoiesis and the immune response in HTLV-I adult T-cell leukemia. Blood 113: 4914-4917.